ChapterPDF Available

Cognitive Impairments in Drug Addicts

Cognitive Impairments in Drug Addicts
Fred Nyberg
Department of Pharmaceutical Biosciences, Uppsala University
1. Introduction
Recent work exploring the effects of abusing alcohol, central stimulants, and opiates on the
central nervous system (CNS) have demonstrated a variety of adverse effects related to
mental health. In several laboratories and clinics substantial damages of brain function are
seen to result from these drugs. Among the harmful effects of the abusing drugs on brain
are those contributing to accelerated obsolescence. These putative aging effects including
inhibition of neurogenesis and enhanced apoptosis underline the dark side of drug
addiction and will doubtlessy be a challenge for future research (Carvalho, 2009). An
observation that has received special attention during recent years is that chronic drug users
display pronounced impairment in brain areas associated with executive and memory
function (Ersche et al., 2006).
Addiction to drugs is characterized as a compulsive behavior, including drug seeking, drug
use, and drug cravings but it is also considered as a disorder of altered cognition (Gould,
2010). Indeed, brain areas and processes involved in drug addiction substantially overlap
with those known to be of relevance for cognitive functions. Studies have indicated that
abusing drugs may alter the normal structure in these regions and influence functions that
induce cognitive shifts and promote continued drug use. Processes during early stages of
drug abuse is suggested to promote strong maladaptive connections between use of drugs
and environmental input underlying future cravings and drug-seeking behaviors.
Continued drug use causes cognitive deficits that aggravate the difficulty of establishing
sustained abstinence (Gould, 2010). In fact, drug addiction has been characterized as a
disease of "pathological learning" by several investigators (Hyman, 2005; Gould, 2010).
In earlier days abusing drugs were considered only to induce non-specific effects on the
brain. Today, it is widely believed that they may produce selective adaptations in very
specific brain regions. These neuroadaptations have been extensively examined in order to
clarify mechanisms underlying the development and maintenance of addiction to find
strategies for relevant treatment. The hippocampus is an area included in the limbic
structures that is of particular interest, as it is found to be essential for several aspects
related to the addictive process. A remarked neuroadaptation caused by addictive drugs,
such as alcohol, central stimulants and opiates involves diminished neurogenesis in the
subgranular zone (SGZ) of the hippocampus. Indeed, it has been proposed that decreased
adult neurogenesis in the SGZ could modify the hippocampal function in such a way that it
contributes to relapse and a maintained addictive behavior (Arguello et al., 2008). It also
Brain Damage – Bridging Between Basic Research and Clinics
raises the possibility that decreased neurogenesis may contribute to cognitive deficits
elicited by these abusing drugs.
In addition to hippocampal structures the prefrontal cortex and its different subregions have
also been hypothesized to represent this cognitive control system (George et al., 2010;
Ridderinkhof et al., 2004). Neurons in the dorsolateral prefrontal cortex are suggested to be
involved in activity that in delayed matching to sample tasks persists throughout the delay
period (Weiss and Disterhoft, 2011). Moreover, age-related changes in the prefrontal cortex
microcolumnar organization are shown to correlate with age-related declines in cognition.
Activity that persists beyond the induction of a specific stimulus is believed to mediate
working memory processes, and disruption of those processes is related to memory deficits
that often accompany the aging process. The prefrontal cortex is known as an area with
enhanced vulnerability to alcohol-induced damage. It is suggested that inhibition of adult
neurogenesis may be a factor that underlie alcohol-mediated cognitive dysfunction, which
in turn may be a cause to decreased behavioral control over consumption (Nixon and
McClain, 2010). Also, an influence of opioids and stimulant drugs on hippocampal
neurogenesis in adults has been confirmed (Eisch et al., 2000). Exposure to psychotropic
drugs is suggested to regulate the rate of neurogenesis in the adult brain, suggesting a
possible role for neurogenesis in the drug-induced impairments seen in cognitive functions
(Duman et al., 2001).
This article is aimed to provide a comprehensive collocation of the impact of abusing drugs
on cognitive functions. It describes adverse effects on learning and memory of selected
drugs and how these compounds interact with neuronal circuits involved in these
behaviors. Possible approaches to deal with these drug-induced damages from the
pharmacological point of view will also be discussed.
2. Memory and learning
Memory is described as a multi-system phenomenon in the brain. Each system has been
associated with a separate memory function targeting different neurological substrates. For
example, declarative memory is attributed to a function of retaining conscious memories of
facts and sights. The establishment of new declarative memories is related to structures in
the diencephalon and the medial temporal lobe, and it has been proposed that these
memory imprints are generated in specific areas of the cerebral cortex. For example, brain
areas implicated in deficits in declarative memory include the prefrontal cortex and the
hippocampus. The frontal cortex is recognized as an important substrate for features related
to reasoning and memory content of the declarative memory (Samuelson, 2011; Weiss and
Disterhoft, 2011). Classical conditioning, skill learning and repetition learning, i.e.
nondeclarative forms of memory, are documented through changes in the way they are
carried out and are not considered to involve conscious recollection. The functional anatomy
of these nondeclarative forms of memory are believed to comprise the basal ganglia,
cerebellum and cerebral cortex.
A concept of synaptic plasticity essential for the storage of long-term memory (LTM) at the
cellular level is the long-term potentiation (LTP). LTP is shown to enhance the signal
transmission between neighboring neurons over a long period of time and it can be induced
by high-frequency stimulation of the synapse, and at this level it represents an important
Cognitive Impairments in Drug Addicts 223
target for studies of memory enhancement. LTP is an attractive candidate for explanation of
cellular mechanisms underlying learning and memory as it shares many features with LTM.
Both LTP and LTM are triggered rapidly, and each of them seems to be dependent on the
biosynthetic process for protein formation and the proteins, which are formed, are belived
to have a role in associative memory and have been suggested to last over a long period of
time. Furthermore, LTP is found to be linked to a number of different types of learning, and
these are shown to include the simple classical conditioning observed in experimental
animals as well as the more complex, higher-level cognition that is experienced by humans
(Cooke and Bliss, 2006).
Although LTP is not demonstrated in all brain regions it has been clearly seen in many
areas, including amygdala, hippocampus, nucleus accumbens and prefrontal cortex, i.e.
regions involved in drug reward but also in memory and learning (Kenney and Gould,
2008). For instance, enhanced activity in amygdala and enhanced amygdala-hippocampus
connectivity leading to long-lasting, non-temporary memory alterations has been described
(Edelson et al., 2011). It was further indicated that the hippocampus is essential for the
transfer of short-term memories to LTMs (Santini et al., 2001; Glannon, 2006). In addition,
clinical investigations including neuropsychological patients as well as studies using
experimental animals have suggested that, in addition to its critical role in the LTM
formation, the hippocampal structure is essential for the integrating and processing of
spatial and coherent information (Kim and Lee, 2011).
The molecular mechanism underlying memory potentiation is suggested to involve the
excitatory amino acid glutamate (Abel and Lattal, 2001). Glutamate binding activates both
the N-methyl-D-aspartyl (NMDA) and the α-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) receptors located on the cell membrane of the nerve cells. These
events lead to the opening of calcium and sodium channels into the nerve cells. The calcium
influx activates the enzyme adenylate cyclase, which in turn converts ATP to cAMP.
Subsequent to this event the cAMP actuates a sequential activation of protein kinase A,
mitogen-activated protein kinase/extracellular signal-regulated protein kinase, as well as
the cAMP response element-binding factor (CREB). The activated CREB attaches to DNA
and induces transcription and subsequently an increased production of proteins essential
for the construction of new synapses (Abel and Lattal, 2001).
Regarding the NMDA receptor it has been shown in experimental animal models that the
organization of the receptor subunits NR1, NR2A, NR2B and NR2D is essential for the
memory promoting effect of glutamate. For instance, transgenic mice overexpressing the
NR2B subunit exhibit improved performance in memory tests (Tang et al., 1999 ). Also the
ratio of the NR2B to NR2A ratio has been shown as a relevant marker on cognitive
functioning in the rat. Increased ratio of NR2B/NR2A has been seen to increase LTP (Le
Grevès et al., 2002; Le Grevés et al., 2006; Zhao et al., 2005).
A considerable amount of evidence supports an important role for glutamate and its ligand-
gated ionotropic receptors (i.e. NMDA, AMPA, and kainic acid (KA) subtypes) in mediating
addictive behaviors have been collected over the years (Wolf, 1998; Tzschentke and Schmidt,
2003; Kalivas, 2004; Gass and Olive, 2009). However, the role of metabotropic glutamate
(mGlu) receptors in the neural mechanisms underlying drug addiction has become apparent
only within the latest decades (Olive, 2010). Evidence for a role of Group I (mGlu1 and
Brain Damage – Bridging Between Basic Research and Clinics
mGlu5) receptors in regulating drug intake, reward, reinforcement, and reinstatement of
drug-seeking behavior have emerged from recent pharmacological and genetic studies
(Olive, 2009) . However, these kind of mGlu receptors is also suggested to mediate cognitive
processes including learning and memory, behavioral flexibility, and extinction
(Moghaddam, 2004; Simonyi et al., 2005; Gravius et al., 2006; Gass and Olive, 2009) and
deficits in these expressions of cognition are frequently observed in drug addicts.
3. Drug effects on cognitive function
As mentioned above drug addiction is seen as a chronic relapsing disorder with persistent
brain alterations associated with cognitive, motivational and emotional alterations and
studies have indicated the presence of extensive cognitive alterations in many individuals
diagnosed with substance use disorders (Goldstein and Volkow, 2002; Fernández-Serrano et
al., 2010). Thus, over the past decades the influence of abusing drugs on cognitive
capabilities in addicts has been the subject for many studies in various clinical and basic
science laboratories. Although it has been known for long that alcoholism is connected with
deficient memory and learning and seems to accelerate aging processes, negative effects of
chronic use of narcotics on cognitive functions have become evident during more recent
times. This section focuses on adverse effects induced by some frequently used drugs,
including alcohol, central stimulants, and opioids. All these substances have been reported
to affect many aspects of memory and learning.
3.1 Alcohol-induced effects on memory and cognition
Emerging data from past and current research provide evidence for cognitive impairments
of alcohol-dependent patients, particularly regarding their ability to perform tasks sensitive
to frontal lobe function. This fact has brought up the importance of a significant abstinence
allowing individuals with these impairments to recover (Glass et al., 2009; Loeber et al.,
The adverse effect of alcohol on cognitive function is typified by the well-known Wernicke-
Korsakoff syndrome (WKS). This disorder is a neurological disturbance and it is caused by
the lack of thiamine (vitamin B1) in the brain. Its onset is linked to mal nutrition or to
alcoholism. In Western countries WKS is perhaps the most common alcohol-induced
memory disturbance. It is characterized by neuropathological changes in the diencephalon,
including the anterior part of the thalamus, and the mammillary body caused by thiamine
deficiency (Kopelman et al., 2009). The most characteristic neuropsychological feature of
WKS is a marked decline in memory capabilities, whereas other intellectual abilities are
relatively preserved. Alcohol-related dementia is generally defined as alcohol-induced
dementia in the Diagnostic and Statistical Manual of Mental Disorders IV- Text Revision
(DSM-IV- TR). It has been described as an organic brain syndrome induced by over-
consumption of alcohol, which causes severe cognitive impairment, including executive
dysfunction, lack of emotional control and disturbances in memory function (Asada et al.,
Evidence that emerges from experimental studies has shown that early exposure to alcohol
sensitizes the neurocircuitry of addiction and affects chromatin remodeling. These events
could give rise to altered plasticity in reward-related cognitive processes that contribute to
Cognitive Impairments in Drug Addicts 225
vulnerability to drug addiction in adolescents (Guerri and Pascual, 2010). There are
potential mechanisms by which alcohol affects brain development and causes brain
impairments including cognitive and behavioral dysfunctions but also neurochemical
processes underlying the adolescent-specific vulnerability to drug addiction (Guerri and
Pascual, 2010).
Moreover, in heavy episodic drinkers reduced psychomotor speed and a decline in accuracy
when performing tasks of attention, working memory, implicit memory as well as associate
learning and memory have been reported (Cairney et al., 2007). For instance, among the
population of Aboriginal Australians, who were heavy episodic alcoholic users, specific
cognitive abnormalities that suggest frontostriatal abnormalities have been observed in
association with chronic alcoholism (Cairney et al., 2007).
In the brains of alcoholics the frontal lobes, with significant neuronal losses in the superior
frontal cortex, are shown to be the most insulted areas (Kubota et al., 2001; Sullivan and
Pfefferbaum, 2005). These lobes are known to regulate complex cognitive skills including
working memory, attention, temporal ordering, mood, motivation, risk taking and wanting
as well as discrimination and reversal learning that underlie judgment. Studies have
revealed that a complicated mechanism may underlie alcohol-induced damage to the brain.
Also, the mechanism underlying the abstinence-induced regeneration seems to be complex.
The magnitude of neurodegeneration and the potential for recovery and regeneration vary
between different regions of the brain and seem to be dependent on several factors, such as
pattern of intake, age and genetics (Crews and Nixon, 2009). Moreover, binge ethanol
exposure of rats is seen to reduce hippocampal neurogenesis (Nixon and Crews, 2002) and
brain degeneration in the binge ethanol treatment model is generally widely circulated and
diffused, in similarity to what is observed in human alcoholics.
A recent study performed in order to investigate the harmful effects of binge alcohol on the
hippocampal neurogenesis in adolescent non-human primates suggested that the liquid
drug may interfere with the migration and distribution of hippocampal preneuronal
progenitors (Taffe et al., 2010). Furthermore, the decreased neurogenesis induced by alcohol
in the hippocampus was seen to be paralleled by an increase in neural degeneration thought
to be mediated by non-apoptotic pathways. This effect remained for quite a long time
following alcohol discontinuation and it was suggested to cause the deterioration in
hippocampus-associated cognitive tasks that are frequently seen in alcoholics (Taffe et al.,
Regarding the mechanism underlying alcohol-induced neurodegeneration and cognitive
impairment the involvement of glutamatergic neurotransmission seems well documented,
however, many details of the underlying mechanism remains unknown. Studies have been
focused both on the NMDA receptor system and the group II metabotropic glutamate
receptor. A recent study examined the effect of the agonist LY379268 on its ability to
prevent neuronal death and learning deficits in a rat model of binge-like exposure to alcohol
(Cippitelli et al., 2010). It was found that neurodegeneration was most extensive in the
ventral hippocampus and the entorhinal cortex (EC) and the glutamate receptor agonist was
potently neuroprotective in the EC but not in the dentate gyrus of the hippocampus. In
additional experiments, binge alcohol exposure suppressed the expression of transforming
growth factor beta (TGF-beta) expression in both the EC and dentate gyrus, while the
Brain Damage – Bridging Between Basic Research and Clinics
glutamate agonist increased TGF-beta in the EC only. It was further reported that the
neuroprotective effects of the glutamate agonist were paralleled with prevention of deficits
in spatial reversal learning. These data was considered to give support for a protective role
of TGF-beta and group II metabotropic glutamate receptor agonists in alcohol-induced
neurodegeneration (Cippitelli et al., 2010).
However, studies have confirmed that alcohol may damage specific regions both in the
adult and the adolescent brain (Alfonso-Loeches and Guerri, 2011). The mechanisms behind
this damage is suggested to involve excitotoxicity, free radical formation and
neuroinflammatory destructions caused by activation of the immune system and mediated
through Toll-like receptor 4 (TLR4 receptor). Alcohol is also shown to act on specific cell
surface receptors, e.g. the NMDA, GABA-A receptors and on certain ion channels, like L-
type Ca²+ channels and GIRKs but the drug is also found to interact with various signaling
pathways, e.g. PKA and PKC signaling. All these multi-targets are belived to underlie the
wide variety of behavioral effects seen to result from chronic intake of ethanol (Alfonso-
Loeches and Guerri, 2011).
Several effects of alcohol seems to involve the endogenous opioid systems (EOS). Opioid
peptides, including beta-endorphin, have a role in mediating the reward effect of the
drug. However, also some adverse effects are mediated through the EOS. A recent study
on human alcohol-dependent subjects investigated whether the EOS is altered in brain
areas involved in cognitive control of addiction. Human post-mortem brain specimens,
including the dorsolateral prefrontal cortex (dl-PFC), orbitofrontal cortex (OFC) and
hippocampus, from alcoholic and control subjects were examined. The expression of the
prodynorphin gene transcript and dynorphin peptides in dl-PFC, the κ-opioid peptide
(KOP) receptor message in OFC and dynorphins in hippocampus were all up-regulated in
alcoholics. No significant changes in expression of other EOS gene transcripts were
reported. Activation of the KOP receptor by the up-regulated dynorphin peptides in
alcoholic brains was suggested to at least partly underlie neurocognitive dysfunctions
relevant for addiction and disrupted inhibitory control (Bazov et al., 2011). In a
subsequent study focused on genetic, epigenetic and environmental factors and their
influence on the risk for alcoholism the result was indicative of a causal link between
alcoholism-associated prodynorphin 3'-UTR CpG-SNP methylation, activation of
prodynorphin transcription and vulnerability of individuals with the C, non-risk allele(s)
to develop alcohol dependence (Taqi et al., 2011).
A study highlighting the specific attentional processes impaired in alcoholics concluded
that a representative sample of alcoholics show specific deficits of attention as opposed to
a general decline of attention at treatment intake. It was thus reported that sober
alcoholics appear to be as efficient as controls at selecting on the basis of location,
however, when they are required to select on the basis of semantic information or
required to respond to two independent sources of information they are at a deficit
(Tedstone and Coyle, 2004).
Taking together it appears that chronic alcohol intake under a variety of condiditions
impairs cognitive factors including various aspects of memory and learning, attention, risk
taking, motivation, mood and wanting. Specific brain areas targeted by the drug in this
context includes hippocampus and frontal cortex. The mechanisms underlying the effects of
Cognitive Impairments in Drug Addicts 227
ethanol involve inhibition of neurogenesis and interaction with a number of signal
pathways, including glutamate, monoamines and endogenous opioids.
3.2 Effects of central stimulants on cognition
Epidemiological studies have confirmed a high prevalence of stimulant drugs and that these
drugs are being used increasingly over the past decades (Gonzales et al., 2010; Ciccarone,
2011; Vardakou et al., 2011). They have been taken in order to enhance social or cognitive
performance but also to induce euphoria and wellbeing. However, chronic use of these
drugs has been associated with substantial deficits in learning and verbal memory. Thus the
harmful consequences of long-term stimulant abuse also seem to include neurodegenerative
effects leading to cognitive disabilities (Ciccarone, 2011; McKetin and Mattik, 1997;
Krasnova et al., 2005).
3.2.1 Amphetamine
The psychostimulant amphetamine is shown to improve cognition in healthy subjects but
also in attention-deficit hyperactivity disorder as well as in other neuropsychiatric disorders.
However, at higher doses the stimulant may induce impaired cognitive function (Reske et
al., 2010), particularly those mediated by the prefrontal cortex (Xu et al., 2010). Also, chronic
use of amphetamine induces significantly impaired performance in cognitive tests (Ornstein
et al., 2000). Data has indicated that amphetamine as well as other psychostimulants affects
the capacity of the brain to stimulate neurogenesis, and that their effects also include
disruption of the blood-brain barrier (BBB) (Silva et al., 2010). Thus, in chronic use the
psychostimulatory effect of amphetamine is not only connected with reward and euphoria
but also with impairments in attention and memory. These cognitive deficits have been
suggested to be related to neurotoxic effects of the drug (Krasnova et al., 2005).
Amphetamine injection is shown to affect dopaminergic terminals in striatal cells and to
increase levels of cleaved caspase-3, a marker of apoptosis. Furthermore, the stimunlant is
also demonstrated to increase the expression of p53 and Bax at both transcriptional and
protein levels, whereas it decreased the levels of the Bcl-2 protein, all these events in
agreement with increased apopotosis (Krasonova et al., 2005). Amphetamine is also shown
to affect dopamine circuits in the prefrontal cortex (Dunn and Killcross, 2007; Fletcher et al.,
2007) and thereby inducing impaired cognitive function.
3.2.2 Cocaine
Long-lasting memory deficits have been seen in individuals chronically abused to cocaine
(Beatty et al., 1995; Bolla et al., 1999), although some ambiguities in respect to the specificity
of this impairment remain to be fully clarified. Also, in studies using preclinical models of
addiction it was demonstrated that stress and mechanisms related to the HPA-axis may
contribute to impaired learning (Ehninger and Kempermann, 2006). In a more recent study
it was shown that the deficiences in learning and memory seen in individuals addicted to
cocaine are associated with increased levels of cortisol but also with the outcomes of cocaine
use after inpatient treatment (Fox et al., 2009). Learning-related deficits was found to include
poor immediate and retardent verbal recall and recognition as well as a selective reduction
in working memory. These findings were seen to be in congruence with studies implicating
Brain Damage – Bridging Between Basic Research and Clinics
that neuroadaptations in cocaine addicts affects learning and memory function, which in
turn, appeared to affect the outcomes of drug use (Fox et al., 2009).
Sudai and collaborators investigated the effects of cocaine on cell proliferation and
neurogenesis in the hippocampal dentate gyrus of adult rats (Sudai et al., 2011). The
influence of the stimulant drug on working memory during abstinence was examined using
the water T-maze test. Results suggested that cocaine, in addition to its effects on the reward
system, also may inhibit the generation and development of new cells in the hippocampus,
and thereby reduce the capacity of the working memory (Sudai et al., 2011).
In studies on mechanisms underlying the effects of cocaine on memory function several
laboratories have focused on brain circuits and transmitter substances known to be involved
in stress and memory formation. Muriach and collaborators described a study on nuclear
factor kappa B (NFKappaB). NFKappaB is known as a sensor of oxidative stress and it is
demonstrated to have a role in memory formation that could be involved in addiction
mechanisms. They reported a mechanistic role of NFKappaB in alterations induced by
cocaine and observed memory disabilities that was impaired and correlated negatively with
the NFkappaB activity in the frontal cortex (Muriach et al., 2010). Cocaine has also been
shown to induce neuroadaptive effects in hippocampal regions by enhancing LTP through
interaction with the dopamine transporter and a subsequent enhancement of dopamine
(Thomson et al., 2005). Subsequent studies have confirmed that endogenous dopamine in
the presence of cocaine facilitates the elevation of basal hippopcampal LTP (Stramiello and
Wagner, 2010). Cocaine may also induce impairments in working memory by action on
dopaminergic circuits in the prefrontal cortex (George et al., 2008).
3.2.3 Methamphetamine, ecstasy and mephedrone
In addition to amphetamine, during the past years chronic use of several stimulant drugs
with similar structure have been shown to impair cognitive functions. Among these
compounds are methamphetamine, ecstasy and perhaps also cathinones (Gouzoulis-
Mayfrank and Daumann, 2009; Rogers et al., 2009; Hoffman and Al'Absi, 2010). All these
substances are not in clinical use and are classified as illegal drugs. They are easily accessible
at internet and are misused in many countries. Regarding their mechanism of action ecstasy
was shown to cause selective and persistent damages on central serotonergic nerve
terminals, while methamphetamine produces lesions in both the serotonergic and
dopaminergic systems. Also mephedrone seems to affect both transmitter systems (Kehr et
al., 2011).
Chronic methamphetamine is shown to cause persisting cognitive deficits in human addicts
as well as in animals exposed to this central stimulant (Reichel et al., 2011). Recent findings
suggest that methamphetamine may induce a hypofunction in cortical areas that are
important for executive function that in turn underlies the cognitive control deficits seen in
individuals dependent on this drug (Nestor et al., 2011).
Methamphetamine-induced changes in the serotonin transporter SERT function in areas
associated with cognition may underlie memory deficits independently of overt neurotoxic
effects (Reichel et al., 2011). Moreover, data has indicated that also the σ receptors may be
implicated in various acute and subchronic effects of methamphetamine. These include
locomotor stimulation, development of sensitization and neurotoxicity, effects that may be
Cognitive Impairments in Drug Addicts 229
attenuated by σ receptor antagonists. The σ receptors are also suggested to be involved in
methamphetamine-induced deficits in cognitive and motor function (Kaushal and
Masumoto, 2011).
Abuse of methamphetamine has also been seen to result in impaired adult hippocampal
neurogenesis, and effects of this stimulant drug on neural progenitor cells is suggested to be
mediated by protein nitration (Venkatesan et al., 2011). This observation was considered to
open for new strategies regarding design and development of therapeutic approaches for
methamphetamine-abusing individuals with neurologic dysfunction or even for other
disorders with impaired hippocampal neurogenesis.
Use of ecstasy is shown to reduce cognitive functioning by reducing levels of dopamine and
serotonin in CNS areas of importance for memory and learning (Gouzoulis-Mayfrank and
Daumann, 2009; Chummun et al., 2011). Ecstasy is an abusing drug related to amphetamine
and can act as a stimulant producing euphoria by enhancing dopamine levels in the nucleus
accumbens in conformity to but to a lesser extent than amphetamine and cocaine. However,
ecstasy may also interact with serotonergic payhways and long term exposure to this drug
results in decreased activity in both serotonin and dopamine neurons (Kehr et al., 2011). The
reduction in these transmitter systems is seen as dose-related impairments in cognitive
function, in particular regarding complex cognitive skills. The decreased serotonergic and
dopaminergic activity is also believed to cause changes in mood, hallucinations, altered
perception and memory loss. Previous and current research demonstrate that abusing
ecstasy is strongly associated with deteriorated working memory, and that this worsening
correlates to the total lifetime of ecstasy consumption. These findings stresses the long-term,
cumulative behavioral manifestations linked to ecstasy use in humans (Nulsen et al., 2010).
Ecstasy users often show decreased levels of serotonin, its metabolite 5-HIAA, tryptophan
hydroxylase and SERT density during abstinence. They also display functional impairments
in learning and memory but also in higher cognitive processing, as well as sleep disturbance
and deficits related appetite and reduced psychiatric wellbeing (Canales, 2010). These
psychobiological impairments appeared most pronounced in heavy ecstasy users and may
reflect losses in serotonergic axones in certain brain regions, in particular the frontal lobes,
temporal lobes and hippocampus. These complications seem to last long after cessation of
ecstasy use, suggesting that these drug-induced neurological impairments may be
permament. It is believed that at least some of the harmful effects on memory of ecstasy
abuse could result from its neurotoxic actions on adult hippocampal neurogenesis. Evidence
suggests that stimulant abuse negatively affects cognitive functions that are regulated and
influenced by adult hippocampal neurogenesis, including contextual memory, spatial
memory, working memory and cognitive flexibility (Canales, 2010).
4-methylmethcathinone (mephedrone) represents a designer stimulant that is among the
most popular of the naturally occurring psychostimulant cathinone derivatives. A web-
based survey has shown that mephedrone users consider the effects of this drug to compare
best with those of ecstasy (Carhart-Harris et al., 2011), which agrees with research studies
comparing the effects of mephedrone and ecstasy on brain 5HT and dopamine (Kehr et al.,
2011). This cathinone has been readily available for purchase both online and in the streets
and has been promoted by aggressive web-based marketing. Its abuse in many western
countries has been described as a serious public health concern (Hadlock et al., 2011). In
conformity with ecstasy, metamphetamine and methcathinone, repeated mephedrone
Brain Damage – Bridging Between Basic Research and Clinics
injections causes a rapid decrease in the striatal dopamine and in the hippocampal 5HT
transporter function. Mephedrone is also shown to inhibit both synaptosomal dopamine
and 5HT reuptake. Similar to ecstasy but unlike methamphetamine or methcathinone,
repeated mephedrone also causes persistent serotonergic, but not dopaminergic, deficits
(Hadlock et al., 2011, Kehr et al., 2011). No studies on learning and memory impairments in
mephedrone abusers has yet been published, however, due to similarieties with ecstasy and
methamphetamine research investigating the actual domains of cognition in chronic and
abstinent mephedrone users seems to be warranted in the future.
4. Opioid-induced adverse effects on cognitive functions
A variety of neuropathologic adaptations have been detected in the brains of heroin addicts.
These include pathology caused by bacterial infections, viral infections, such as HIV-1
infection, but also complications such as hypoxic–ischemic encephalopathy with cerebral
edema, ischemic neuronal damage and neuronal loss (Büttner et al., 2000). However, chronic
exposure to opiates, such as heroin, morphine and to some extent also methadone are
shown to impair cognitive function (Mintzer and Stiltzer, 2002; Gruber et al., 2007; Soyka et
al., 2011). Heroin is characterized as one of the most frequently abused illegal drugs, and
addiction to this drug is linked to significant attention deficits and inadequate performance
on memory tasks (Guerra et al., 1987). Furthermore, chronic exposure to morphine is also
shown to cause vigilance and attention impairments in chronic pain patients (Mao et al.,
2002) and impairs acquisition of reference memory in rats (Spain and Newsom, 1991; Lu et
al., 2010). Also addicts in methadone maintenance programs or chronic pain patients treated
with methadone are shown to display cognitive impairmats (Mitzler and Stitzer, 2002;
Soyka et al., 2010). These findings suggest an effect of chronic opiates on brain regions
related to learning and memory, such as the frontal cortex (Ornstein et al., 2000; Yang et al.,
2009) and the hippocampus (Lu et al., 2010)
Regarding the mechanisms by which opioids induce cognitive impairments through action
on hippocampal and prefrontal cortex structures it is shown that these drugs may enhance
apoptosis and inhibted neurogenesis. An opioid-induced attenuation of neurogenesis in
hippocampus was earlier seen in male rats exposed to morphine (Eisch et al., 2000). Thus,
opiates, such as morphine, is seen to reduce neurogenesis in the adult hippocampal
subgranular zone (SGZ), suggesting that a waning neurogenesis contributes to opioid-
induced deficits in cognitive function (Arguello et al., 2008). Enhanced apoptosis following
exposure to opioids was reported to involve an upregulation of the proapoptotic caspase-3
and Bax proteins following NMDA receptor activation (Mao et al., 2002). Also, chronic
methadone have been shown to up-regulate several pro-apoptotic proteins in the cortex and
hippocampus, indicating activation of both the NMDA-receptor and mitochondrial
apoptotic pathways (Tramullas et al., 2007). In addition, morphine-induced expression of
the Toll-like receptor 9 (TLR9) and microglia apoptosis was suggested to involve the μ-
opioid peptide receptor, MOP (He et al., 2011). It was further suggested that inhibition of
the TLR9 and/or blockage of the MOP receptor may be a possible route for preventing
opioid-induced brain damage.
The opiate elicited apoptosis in human fetal microglia and neurons (Hu et al., 2002), was
also associated with morphine tolerance (Mao et al., 2002). The apoptotic effect of morphine
is blocked by the opioid receptor antagonist naloxone (Hu et al., 2002), indicating an opioid
Cognitive Impairments in Drug Addicts 231
receptor mechanism involved in this effect. The effect of morphine is known to be mediated
mainly through the MOP receptor although, at high concentrations, this opiate is known
also to interact with both the delta-opioid peptide (DOP) and the KOP receptors.
Furthermore, it appears that the opioid receptor subtypes (MOP, DOP, and KOP) may
regulate different aspects of neuronal development (Hauser et al., 2000). Evidence
suggesting that the MOP receptor could play an important role in regulating progenitor cell
survival has recently been described (Harburg et al., 2007). In addition, morphine was
earlier shown to promote anomal programmed cell death by increasing the expression of the
proapoptotic Fas receptor protein and decreasing the expression of the antiapoptotic Bcl-2
oncoprotein by maintaining the activation of opioid receptors (Boronat et al., 2001). Studies
also indicated that opiate-induced alteration of hippocampal function most likely results
from inhibited neurogenesis (Eisch and Harburg, 2006).
5. Reversal of drug-induced impairments of abusing drugs
It is obvious from the above that chronic use of many addictive drugs may elicit pronounced
effects on brain structures associated with cognitive functions leading to impaired learning
and memory capabilities. It is not yet clarified whether the effects are reversible or persist
over the life time. However, it seems that for many individual addicts these drug-induced
damages may contribute to accelerated senescence. Many attempts to develop therapeutic
strategies to deal with this complication have been reported. Indeed, attempts to design
molecules that may counteract these deficits and enhance cognitive capabilities have been
reported over the past decade. Several approaches to reverse cognitive impairmnts induced
by central stimulanta have been reported. In the following this article will describe attempts
to reverse morphine-induced damage in the hippocampus with the far aim to reconstitute
cognitive abilities in experimental animals exposed to opioids.
5.1 Attempts to reverse of opioid-induced impairments on cognition
In a previous study we demonstrated that a single dose of morphine may affect the expression
of the growth hormone (GH) receptor as well as the GH binding protein (GHBP) in the rat
hippocampus. The gene transcripts were significantly attenuated 4 h following drug injection
but was restored after 24 h (Thörnwall-LeGreves et al., 2001). In rats chronically treated with
morphine, a decrease in GH binding was observed during the acute phase but this alteration
was restored when animals were tolerant to the drug (Zhai et al., 1995).
As mentioned above, chronic morphine may reduce neurogenesis in the granule cell layer of
hippocampus in the adult rat and a similar effect was seen in male rats after chronic self-
administration of heroin (Eisch et al., 2000). Furthermore, studies have shown that opioid
effects on nerve cell regeneration is not mediated through interactions with the HPA-axis, as
similar effects were found also in rats subjected to adrenalectomy and subsequent
corticosterone replacement. These observations suggest that the opioid regulation of
neurogenesis in the adult rat hippocampus may be mediated by direct effects of the opioid
drugs on the hippocampal function. The recent study by Arguello and co-workers, as
mentioned above, demonstrated that chronic morphine attenuates neurogenesis in the SGZ
by impeding cell-dividing, primarily in the S-phase, and inhibiting progenitor cell
progression to a more mature stage (Arguello et al., 2008). In order to find strategies to
reverse the opioid-induced damage to the hippocampal function it is essential to look for
Brain Damage – Bridging Between Basic Research and Clinics
agents that may stimulate hippocampal progenitors and thereby increase neurogenesis and
regeneration of nerve cells. The above mentioned opioid effects on GH and its receptor
suggest that the somatotrophic axis may be of importance in this regard. Indeed, both GH
and its mediator insulin-like growth factor-I (IGF-I) have been reported to induce
neuroprotective effects and also stimulate neurogenesis (Isgaard et al., 2007; Nyberg, 2009).
5.1.1 The impact of the somatotrophic axis on neuroprotection
Data indicating a substantial impact of the somatotrophic axis on nerve cell regeneration has
been reported (Isgaard et al., 2007). IGF-I treatment was found to promote cell genesis in the
brains of adult GH- and IGF-1-deficient rodents (Anderson et al., 2002; Aberg et al, 2009). In
the hippocampus, treatment with bovine GH (bGH) induced an increase in the number of
BrdU/NeuN-positive cells proportionally to the recorded increase in the number of BrdU-
positive cells. In vitro incorporation of 3[H]-labeled thymidine demonstrated that short-time
exposure to bGH enhanced the cell proliferation in adult hippocampal progenitor cells. This
observation demonstrated that peripherally administrated GH may increase the number of
new cells in the brain of adult rats and that the hormone may exert a direct proliferative
effect on neuronal progenitor cells (Aberg et al., 2006; Aberg et al., 2009).
Positive effects of GH on neurogenesis have been observed in several laboratories. A study
by Harvey and co-workers showed that the hormone is produced in the retinal ganglion
cells of embryonic chicks, in which GH stimulates cell survival during neurogenesis. The
mechanism underlying this action was investigated in neural retina explants collected from
6-8 days-old embryos. These explants were allowed to incubate with GH for some days and
the hormone was seen to reduce the number of spontaneous apoptotic cells. This anti-
apoptotic action of the hormone was accompanied by a reduction in the expression of the
apoptotic marker caspase-3 but also by a reduced expression of the caspase independent
apoptosis inducing factor-1. These actions were considered specific, since other constituents
known to be involved in apoptotic signaling, such as bcl-2, bcl-x and bid, remained
unaffected. The result from this study was suggested to indicate that GH-induced retinal cell
survival involved pathways dependent and independent on caspase activity (Harvey et al.,
Studies over the past decades have clearly demonstrated that GH targets many areas of the
CNS (for reviews, see Nyberg, 2000; 2007), and that GH deficits has been associated with
cognitive impairments, memory loss, as well as diminished well being (Bengtsson et al.,
1993: Burman and Deijen, 1998). GH replacement therapy in GH-deficient patients was
demonstrated to ameliorate several adverse symptoms seen in these patients (Bengtsson et
al., 1993: Burman and Deijen, 1998; McMillan et al., 2003). The hormone was also found to
prevent neuronal loss in the aged rat hippocampus, confirming a neuroprotective effect of
GH in old animals (Azcoitia et al, 2005). Decreased levels of circulating GH with age (van
Dam et al., 2002) declining density of GH-binding sites with aging was found in several
areas of the human brain, including the hippocampus (Lai et al., 1993). GH was also seen to
enhance the expression of the rat hippocampal gene transcript of the NMDA receptor
subunit NR2B (Le Greves et al., 2002). This receptor subunit is known to enhance memory
and cognitive capabilities in an age-dependent manner while overexpressed (Tang et al.,
1999). In addition, studies showed that GH replacement in hypophysectomized male rats
may improve spatial performance and increase the hippocampal gene transcript levels of
Cognitive Impairments in Drug Addicts 233
some of the NMDA receptor subunits as well as the postsynaptic density protein 95
(Le Greves et al., 2006; 2011). All together, these observations were considered to indicate a
link between decreased GH levels in elderly and deterioration of cognitive functions, with a
clear indication that the hormone may improve memory and cognitive capabilities and this
may be compatible with increased neurogenesis as a result of GH administration.
The mechanism by which GH induces its beneficial effects on memory and cognition is
still not clarified in all its details. However, GH is shown to promote nerve cell
regeneration as well as gliogenesis during the development of the fetal rat brain (Ajo et
al., 2003), presumably through local production of IGF-1. Peripheral administrated GH
reaching the CNS may induce a release of IGF-1 in the brain and this factor may in turn
account for the mediation of brain effects of GH. However, local production of both GH
and IGF-1 in certain areas of the brain has been suggested, as mice with decreased levels
of circulating GH and IGF-1 exhibit normal levels of the corresponding gene transcripts in
the hippocampus (Sun et al., 2005). Also, GH is shown to be produced in the hippocampal
formation, where it is suggested to be involved in functions associated with his region,
such as learning and response to stress (Donahue et al., 2006). Effects on these behaviors
may be caused by the action of GH-induced release of IGF-1 as this mediator is also
shown to affect hippocampal related behaviors. In fact, intracerebroventricular
administration of IGF-1 was found to attenuate the age-related decline in hippocampal
neurogenesis in rats (Lichtenwalner et al., 2001). Moreover, peripheral infusions of IGF-1
were seen to induce neurogenesis in the hippocampus of the adult rat (Aberg et al., 2000)
and overexpression of IGF-1 promotes neurogenesis during the postnatal development
(O’Kusky et al., 2000).
5.1.2 Reversal of opioid-induced impairments by growth hormone
In addition, a recent study showed that chronic morphine significantly and dose-
dependently attenuates neuronal cell density in cultured hippocampal cells from murine
fetus (Svensson et al., 2008). The ability of morphine as well as other opioids to inhibit cell
growth and induce apoptosis is already known from previous work as described earlier in
this section (see section 4). Therefore, the decline observed in neurite outgrowth in the
mouse hippocampal primary cell cultures (Nyberg, 2009; Svensson et al., 2008) was
expected, and a consequence of this decline should be that markers of apoptosis, such as
lactate dehydrogenase (LDH) and caspase-3, will be affected. In fact, the activity and level of
these enzymes were found to be significantly enhanced (Svensson et al., 2008). The
enhanced activity of LDH in morphine-treated hippocampal cells strongly indicates that
morphine may induce apoptosis in cells of this brain area. LDH, a mitochondrial
dehydrogenase, is known to represent a critical component of the astrocyte–neuron lactate
shuttle. It regulates the formation of lactate and influences its turnover within the cells.
Caspase-3 is another enzyme that serves as a marker of apoptosis and cleaved caspase-3
represents an activated form of this enzyme that acts as a lethal protease at the most distal
stage of the apoptotic pathway (Kuribayashi et al., 2006). This enzyme was also investigated
in order to clarify whether the reduction seen in the hippocampal cell density involves
elements related to apoptosis. It was noted that the level of cleaved caspase-3, measured by
Western blot analysis, was significantly enhanced by chronic morphine (Svensson et al.,
Brain Damage – Bridging Between Basic Research and Clinics
As noted above, the hippocampus represents a brain area localized within the limbic system
and is well known as an important brain substrate required for the acquisition of declarative
or explicit memory (Benfenati, 2007). From the literature cited above, it is evident that
chronic administration of opiates may counteract cell growth and stimulate apoptosis, but it
is also demonstrated that opiate-induced toxicity may include impaired neurogensis
(Hauser et al., 2000; He et al., 2002; Mao et al., 2002; Eisch and Harburg, 2006). An impact of
adult-generated neurons on learning and memory was earlier suggested as training on
associative learning tasks was found to double these neurons in the rat brain dentate gyrus
(Kenney and Gould, 2008; Gould, 2010). Consequently, memory dysfunctions induced by
chronic exposure to opiates could result from decreased adult neurogenesis as these drugs
may inhibit neurogenesis in the adult hippocampus (Eisch and Harburg, 2006; Eisch et al.,
2000). This inhibition might well reflect a decreased number of neural precursors caused by
increased apoptosis of the newborn neurons. However, in recent years, several factors that
may promote and enhance neurogenesis from preexisting neuronal precursors have been
reported. Among them are GH and its mediator IGF-1 in addition to several other growth
factors. IGF-1 is shown to be essential for hippocampal neurogenesis (Aberg et al., 2000,
2006). As mentioned above, this factor is regulated through the somatotrophic axis, where
GH has an important role as an activator and releaser of IGF-1 as well as its binding
In order to investigate whether GH may reverse opiate-induced apoptosis or inhibition of
neurogenesis, we examined the effect of human GH on murine primary hippocampal
neuronal cell cultures exposed to morphine (Svensson et al., 2008). We observed that GH
could significantly reverse the morphine-induced inhibition of neurite outgrowth and that
cell density was restored after treatment with the hormone. The effect of GH was evident
both when the hormone was added with morphine and when it was added after the opiate
had induced its damaging effect. We also noted that GH reversed the morphine-induced
effects on the apoptopic markers LDH and caspase-3 activity (Svensson et al., 2008). Thus,
combining these observations with the effects of GH seen on memory and spatial
performance in rats (Le Greves et al., 2006,; 2011) it appears that the hormone may be useful
for the reversal of the adverse effects of morphine or other opiates on brain cells.
These data opens for future attemps also to use IGF-1 in order to reverse opioid-induced
damage on the brain to improve cognitive capabilities. It also opens for the possibility to
stimulate the somatotrophic axis to reverse cognitive impairments induced by other drugs
of abuse. Actually, as can be seen below, growth factors have been used in attempt to
counteract brain damages induced by alcohol.
5.2 Attempts to reverse alcohol-induced impairments in cognition
Studies on the reversal of the adverse effects induced by various drugs have shown that
certain growth factors may be useful in attempts to counteract drug-induced cell damage
and apoptosis. For instance, it was demonstrated (Gibson et al. 2002) that stimulation of
human embryonic kidney cells HEK 293 and the breast cancer cell line MDA MB 231 with
epidermal growth factor (EGF) effectively and dose-dependently protected these cells from
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. This
stimulatory effect was shown to reduce apoptosis by blocking both TRAIL-mediated
Cognitive Impairments in Drug Addicts 235
mitochondrial release of cytochrome c and activation of caspase-3. It was further shown that
the survival response of EGF involved the activation of the protein kinase Akt. Activation of
Akt was found to be sufficient for inibition of the TRAIL-induced apoptosis, and the
expression of kinase-inactive Akt abolished the protective effect of EGF. In contrast,
inhibition of the stimulatory effect of EGF on the extracellular-regulated kinase (ERK)
activity did not affect EGF protection. From these findings it was concluded that activation
of the EGF receptor generates a survival response against TRAIL-induced apoptosis by
blocking the release of cytochrome c from the mitochondria, which, in turn, is mediated by
the activation of Akt in epithelial-derived cells.
The effects of estrogens and certain growth factors subsequent to ethanol treatment were
recently examined in order to assess the potential of these hormones to reverse the effects of
ethanol-induced damage (Barclay et al., 2005). The result of these studies indicated that both
IGF-I and bovine basic fibroblast growth factor (bFGF) reduced toxic effect of the drug on
neuronal survival, whereas estrogen, bFGF, and nerve growth factor (NGF) seemed to
increase the total neurite length after ethanol treatment (Barclay et al., 2005). In addition,
heparin-binding epidermal growth factor (HB-EGF), also a member of the EGF family of
growth factors, has been reported to prevent apoptosis and differentiation and, in a very
recent study, it was shown that stimulation with HB-EGF could reverse alcohol-induced
apoptosis in human embryonic stem cells (Nash et al., 2009). Another possibility for
reversing alcohol-induced cell damage involves brain-derived neurotrophic factor (BDNF).
BDNF signaling plays an important role in neural survival and differentiation and studies
have shown that alcohol significantly reduces BDNF signaling in neuronal cells (Climent et
al., 2002). Also, the antiproliferative action of ethanol can be modulated by changing the
sensitivity of the autophosphorylation of the IGF-1 receptor to ethanol (Seiler et al., 2000).
This raised the question of whether IGF-1 could counteract the antiproliferative effects
induced by alcohol. In fact, studies have shown that alcohol inhibits differentiation of the
neural stem and that this effect is reduced by both IGF-1 and BDNF (Tateno et al., 2004).
These results suggest the possibility that stimulation of neurotrophic factor signaling can
reverse apoptosis induced by alcohol exposure.
6. Conclusions
It is evident from studies reviewed in this article that most drugs of abuse may induce
adverse effects on brain structures associated with cognitive functions. In most cases these
effects seem to impact brain circuits linked to important aspects of cognition, such as
memory and learning, attention, risk taking, motivation, mood and wanting. The deficits
induced on these behaviors by alcohol and opioids are well documented, whereas those of
central stimulants and other abusing drugs are less well characterized. As mentioned in this
article an important issue is the approach to find strategies to reverse the drug-induced
deficits and in the case of damages induced by alcohol and opioid abuse it seems that
certain growth factors may be useful and open for new methods for successful therapy.
7. Acknowledgment
This work was supported by the Swedish Medical Research Council (Grant 9459) and by
the Swedish Council for Working Life and Social Research.
Brain Damage – Bridging Between Basic Research and Clinics
8. References
Abel T, Lattal KM (2001). Molecular mechanisms of memory acquisition, consolidation and
retrieval. Curr Opin Neurobiol. 11:180-187. Review.
Aberg MA, Aberg ND, Hedbäcker H, Oscarsson J, Eriksson PS (2000). Peripheral infusion of
IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci.
Aberg ND, Brywe KG, Isgaard J (2006). Aspects of growth hormone and insulin-like growth
factor-I related to neuroprotection, regeneration, and functional plasticity in the
adult brain. ScientificWorld Journal. 6:53-80.
Aberg ND, Johansson I, Aberg MA, Lind J, Johansson UE, Cooper-Kuhn CM, Kuhn HG,
Isgaard J (2009). Peripheral administration of GH induces cell proliferation in the
brain of adult hypophysectomized rats. J Endocrinol. 201:141-150.
Ajo R, Cacicedo L, Navarro C, Sanchez-Franco F (2003). Growth hormone action on
proliferation and differentiation of cerebral cortical cells from fetal rat.
Endocrinology. 144:1086-1097.
Alfonso-Loeches S, Guerri C (2011). Molecular and behavioral aspects of the actions of
alcohol on the adult and developing brain. Crit Rev Clin Lab Sci. 48:19-47.
Anderson MF, Aberg MA, Nilsson M, Eriksson PS (2002). Insulin-like growth factor-I and
neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res. 134:115- 122.
Arguello AA, Harburg GC, Schonborn JR, Mandyam CD, Yamaguchi M, Eisch AJ (2008).
Time course of morphine's effects on adult hippocampal subgranular zone reveals
preferential inhibition of cells in S phase of the cell cycle and a subpopulation of
immature neurons. Neuroscience. 157:70-79.
Asada T, Takaya S, Takayama Y, Yamauchi H, Hashikawa K, Fukuyama H (2010).
Reversible alcohol-related dementia: a five-year follow-up study using FDG-PET
and neuropsychological tests. Intern Med. 49:283-287.
Azcoitia I, Perez-Martin M, Salazar V, Castillo C, Ariznavarreta C, Garcia-Segura LM,
Tresguerres JA (2005). Growth hormone prevents neuronal loss in the aged rat
hippocampus. Neurobiol Aging. 26:697-703.
Barclay DC, Hallbergson AF, Montague JR, Mudd LM (2005). Reversal of ethanol toxicity in
embryonic neurons with growth factors and estrogen. Brain Res Bull. 67:459- 465.
Bazov I, Kononenko O, Watanabe H, Kuntić V, Sarkisyan D, Taqi MM, Hussain MZ, Nyberg
F, Yakovleva T, Bakalkin G (2011). The endogenous opioid system in human
alcoholics: molecular adaptations in brain areas involved in cognitive control of
addiction. Addict Biol. 2011 Sep 28. doi: 10.1111/j.
Beatty WW, Katzung VM, Moreland VJ, Nixon SJ (1995). Neuropsychological performance
of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend. 37:247-
Benfenati F (2007). Synaptic plasticity and the neurobiology of learning and memory. Acta
Biomed. 78 Suppl 1:58-66.
Bengtsson BA, Edén S, Lönn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tölli J, Sjöström
L, Isaksson OG (1993). Treatment of adults with growth hormone (GH) deficiency
with recombinant human GH. J Clin Endocrinol Metab. 76:309-317.
Cognitive Impairments in Drug Addicts 237
Blagrove M, Seddon J, George S, Parrott AC, Stickgold R, Walker MP, Jones KA, Morgan MJ
(2011). Procedural and declarative memory task performance, and the memory
consolidation function of sleep, in recent and abstinent ecstasy/MDMA users. J
Psychopharmacol. 25:465-477
Bolla KI, Rothman R, Cadet JL (1999). Dose-related neurobehavioral effects of chronic
cocaine use. J Neuropsychiatry Clin Neurosci. 11:361–369.
Boronat MA, García-Fuster MJ, García-Sevilla JA (2001). Chronic morphine induces up-
regulation up-regulation of the pro-apoptotic Fas receptor and down-regulation of
the anti-apoptotic Bcl-2 oncoprotein in rat brain. Br J Pharmacol. 134:1263-1270.
Burman P, Deijen JB (1998). Quality of life and cognitive function in patients with pituitary
insufficiency. Psychother Psychosom. 67:154-167.
Büttner A, Mall G, Penning R, Weis S (2000). The neuropathology of heroin abuse. Forensic
Sci Int. 2000 Sep 11;113(1-3):435-42.
Cairney S, Clough A, Jaragba M, Maruff P (2007). Cognitive impairment in Aboriginal
people with heavy episodic patterns of alcohol use. Addiction.102:909-915.
Canales JJ (2010). Comparative neuroscience of stimulant-induced memory dysfunction: role
for neurogenesis in the adult hippocampus. Behav Pharmacol. 21:379-393.
Carhart-Harris RL, King LA, Nutt DJ (2011). A web-based survey on mephedrone. Drug
Alcohol Depend. 118:19-22.
Carvalho F (2009). How bad is accelerated senescence in consumers of drugs of abuse?
Adicciones. 21:99-104. English, Spanish.
Chummun H, Tilley V, Ibe J (2010). 3,4-methylenedioxyamfetamine (ecstasy) use reduces
cognition. Br J Nurs. 19:94-100.
Ciccarone D (2011). Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment,
attempts at pharmacotherapy. Prim Care. 38:41-58.
Cippitelli A, Damadzic R, Frankola K, Goldstein A, Thorsell A, Singley E, Eskay RL, Heilig
M (2010). Alcohol-induced neurodegeneration, suppression of transforming
growth factor-beta, and cognitive impairment in rats: prevention by group II
metabotropic glutamate receptor activation. Biol Psychiatry. 67:823-830.
Climent E, Pascual M, Renau-Piqueras J, Guerri C (2002). Ethanol exposure enhances cell
death in the developing cerebral cortex: role of brain-derived neurotrophic factor
and its signaling pathways. J Neurosci Res. 68:213-225.
Cooke SF, Bliss TV (2005). Long-term potentiation and cognitive drug discovery. Curr Opin
Investig Drugs. 6:25-34.
Crews FT, Nixon K (2009). Mechanisms of neurodegeneration and regeneration in
alcoholism. Alcohol Alcohol. 44(2):115-127.
Donahue CP, Kosik KS, Shors TJ (2006). Growth hormone is produced within the
hippocampus where it responds to age, sex, and stress. Proc Natl Acad Sci U S A.
Duman RS, Malberg J, Nakagawa S (2001). Regulation of adult neurogenesis by
psychotropic drugs and stress. J Pharmacol Exp Ther. 299:401-407.
Dunn MJ, Killcross S (2007). Medial prefrontal cortex infusion of alpha-flupenthixol
attenuates systemic d-amphetamine-induced disruption of conditional
discrimination performance in rats.Psychopharmacology (Berl).192:347-355.
Brain Damage – Bridging Between Basic Research and Clinics
Edelson M, Sharot T, Dolan RJ, Dudai Y (2011). Following the crowd: brain substrates of
long-term memory conformity. Science. 333:108-11.
Ehninger D, Kempermann G (2008). Neurogenesis in the adult hippocampus. Cell Tissue
Res. 331:243-250.
Eisch AJ, Harburg GC (2006). Opiates, psychostimulants, and adult hippocampal
neurogenesis: Insights for addiction and stem cell biology. Hippocampus. 16:271-
Eisch AJ, Barrot M, Schad CA, Self DW, Nestler EJ (2000). Opiates inhibit neurogenesis in
the adult rat hippocampus. Proc Natl Acad Sci U S A. 97:7579-7584.
Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ (2006). Profile of executive and
memory function associated with amphetamine and opiate dependence.
Neuropsychopharmacology. 31:1036-1047.
Fernández-Serrano MJ, Lozano O, Pérez-García M, Verdejo-García A (2010). Impact of
severity of drug use on discrete emotions recognition in polysubstance abusers.
Drug Alcohol Depend. 109:57-64.
Fletcher PJ, Tenn CC, Sinyard J, Rizos Z, Kapur S (2007). A sensitizing regimen of
amphetamine impairs visual attention in the 5-choice serial reaction time test:
reversal by a D1 receptor agonist injected into the medial prefrontal cortex.
Neuropsychopharmacology. 32:1122-1132.
Fox HC, Jackson ED, Sinha R (2009). Elevated cortisol and learning and memory deficits in
cocaine dependent individuals: relationship to relapse outcomes.
Psychoneuroendocrinology. 34:1198-1207.
Gass JT, Olive MF (2009). Positive allosteric modulation of mGluR5 receptors facilitates
extinction of a cocaine contextual memory. Biol Psychiatry. 65:717-720.
George O, Mandyam CD, Wee S, Koob GF (2008). Extended access to cocaine self-
administration produces long-lasting prefrontal cortex-dependent working
memory impairments. Neuropsychopharmacology. 33:2474-2482.
Gibson EM, Henson ES, Haney N, Villanueva J, Gibson SB (2002). Epidermal growth factor
protects epithelial-derived cells from tumor necrosis factor-related apoptosis-
inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res.
Glannon W (2006). Psychopharmacology and memory. J Med Ethics. 32:74-78. Review.
Glass JM, Buu A, Adams KM, Nigg JT, Puttler LI, Jester JM, Zucker RA (2009). Effects of
alcoholism severity and smoking on executive neurocognitive function. Addiction.
Goldstein, R.Z., Volkow, N.D. (2002). Drug addiction and its underlying neurobiologi- cal
basis: neuroimaging evidence for the involvement of the frontal cortex. Am J
Psychiatry. 159:1642-1652.
Gould TJ (2010). Addiction and cognition. Addict Sci Clin Pract. 5:4-14.
Gouzoulis-Mayfrank E, Daumann J (2009). Neurotoxicity of drugs of abuse--the case of
methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues
Clin Neurosci.11:305-317.
Gonzales R, Mooney L, Rawson RA (2010). The methamphetamine problem in the United
States. Annu Rev Public Health. 31:385-398.
Cognitive Impairments in Drug Addicts 239
Gravius A, Pietraszek M, Schmidt WJ, Danysz W (2006). Functional interaction of NMDA
and group I metabotropic glutamate receptors in negatively reinforced learning in
rats. Psychopharmacology (Berl). 185:58-65.
Gruber SA, Silveri MM, Yurgelun-Todd DA (2007). Neuropsychological consequences of
opiate use. Neuropsychol Rev. 17:299-315.
Guerra D, Solé A, Camí J, Tobeña A (1987). Neuropsychological performance in opiate
addicts after rapid detoxification. Drug Alcohol Depend. 20:261-270.
Guerri C, Pascual M (2010). Mechanisms involved in the neurotoxic, cognitive, and
neurobehavioral effects of alcohol consumption during adolescence. Alcohol. 44:15-
Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM,
Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG,
Hanson GR, Fleckenstein AE (2011). 4-Methylmethcathinone (mephedrone):
neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp
Ther. 339:530-536.
Harburg GC, Hall FS, Harrist AV, Sora I, Uhl GR, Eisch AJ (2007). Knockout of the mu
opioid receptor enhances the survival of adult-generated hippocampal granule cell
neurons. Neuroscience. 144:77-87
Harvey S, Baudet ML, Sanders EJ (2006). Growth hormone and cell survival in the neural
retina: caspase dependence and independence. Neuroreport. 17:1715-1718.
Hauser KF, Houdi AA, Turbek CS, Elde RP, Maxson W 3rd (2000). Opioids intrinsically
inhibit the genesis of mouse cerebellar granule neuron precursors in vitro:
differential impact of mu and delta receptor activation on proliferation and neurite
elongation. Eur J Neurosci. 12:1281-1293.
He L, Li H, Chen L, Miao J, Jiang Y, Zhang Y, Xiao Z, Hanley G, Li Y, Zhang X, LeSage G,
Peng Y, Yin D (2011). Toll-like receptor 9 is required for opioid-induced microglia
apoptosis. PLoS One. 2011 Apr 29;6(4):e18190.
Hoffman R, Al'Absi M (2010). Khat use and neurobehavioral functions: suggestions for
future studies. J Ethnopharmacol. 132:554-563
Hu S, Sheng WS, Lokensgard JR, Peterson PK (2002). Morphine induces apoptosis of human
microglia and neurons. Neuropharmacology. 42:829-836.
Hyman SE (2005). Addiction: a disease of learning and memory. Am J Psychiatry. 162:1414-
Isgaard J, Aberg D, Nilsson M (2007). Protective and regenerative effects of the GH/IGF-I
axis on the brain. Minerva Endocrinol. 32:103-113.
Kaushal N, Matsumoto RR (2011). Role of sigma receptors in methamphetamine-induced
neurotoxicity. Curr Neuropharmacol. 9:54-57.
Kalivas PW (2004). Glutamate systems in cocaine addiction. Curr Opin Pharmacol. 4:23- 29.
Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011).
Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly
increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J
Pharmacol. 164:1949-1958.
Brain Damage – Bridging Between Basic Research and Clinics
Kenney JW, Gould TJ (2008). Modulation of hippocampus-dependent learning and synaptic
plasticity by nicotine. Mol Neurobiol. 38:101-121
Kim J, Lee I (2011). Hippocampus is necessary for spatial discrimination using distal cue-
configuration. Hippocampus. 21:609-621.
Kopelman MD, Thomson AD, Guerrini I, Marshall EJ (2009). The Korsakoff syndrome:
clinical aspects, psychology and treatment. Alcohol Alcohol. 44:148-154
Krasnova IN, Ladenheim B, Cadet JL (2005). Amphetamine induces apoptosis of medium
spiny striatal projection neurons via the mitochondria-dependent pathway. FASEB
J. 19:851-853 Psychiatry 159, 1642–1652.
Kubota M, Nakazaki S, Hirai S, Saeki N, Yamaura A, Kusaka T (2001). Alcohol consumption
and frontal lobe shrinkage: study of 1432 non-alcoholic subjects. J Neurol
Neurosurg Psychiatry. 71:104-106.
Kuribayashi K, Mayes PA, El-Deiry WS (2006). What are caspases 3 and 7 doing upstream of
the mitochondria? Cancer Biol Ther. 5:763-765.
Lai Z, Roos P, Zhai O, Olsson Y, Fholenhag K, Larsson C, Nyberg F (1993). Age-related
reduction of human growth hormone-binding sites in the human brain. Brain Res.
Le Greves M, Steensland P, Le Greves P, Nyberg F (2002). Growth hormone induces age-
dependent alteration in the expression of hippocampal growth hormone receptor
and N-methyl-D-aspartate receptor subunits gene transcripts in male rats. Proc
Natl Acad Sci U S A. 99:7119-7123.
Le Greves M, Zhou Q, Berg M, Le Greves P, Fholenhag K, Meyerson B, Nyberg F (2006).
Growth hormone replacement in hypophysectomized rats affects spatial
performance and hippocampal levels of NMDA receptor subunit and PSD-95 gene
transcript levels. Exp Brain Res. 173:267-273.
Le Grevès M, Enhamre E, Zhou Q, Fhölenhag K, Berg M, Meyerson B, Nyberg F (2011).
Growth Hormone Enhances Cognitive Functions in Hypophys-Ectomized Male
Rats Am. J. Neuroprotec. Neuroregen. 3:53-58.
Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR (2001).
Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-
related decline in hippocampal neurogenesis. Neuroscience. 107:603-613
Loeber S, Duka T, Welzel H, Nakovics H, Heinz A, Flor H, Mann K (2009). Impairment of
cognitive abilities and decision making after chronic use of alcohol: the impact of
multiple detoxifications. Alcohol Alcohol. 44:372-381.
Lu G, Zhou QX, Kang S, Li QL, Zhao LC, Chen JD, Sun JF, Cao J, Wang YJ, Chen J, Chen XY,
Zhong DF, Chi ZQ, Xu L, Liu JG (2010). Chronic morphine treatment impaired
hippocampal long-term potentiation and spatial memory via accumulation of
extracellular adenosine acting on adenosine A1 receptors. J Neurosci. 30:5058- 5070.
Mao J, Sung B, Ji RR, Lim G (2002). Neuronal apoptosis associated with morphine tolerance:
Evidence for an opioid-induced neurotoxic mechanism. J Neurosci. 22:7650–7661.
McKetin, R., and Mattick, R. P. (1997) Attention and memory in illicit amphetamine users.
Drug Alcohol Depend. 48:235–242.
Cognitive Impairments in Drug Addicts 241
McMillan CV, Bradley C, Gibney J, Healy ML, Russell-Jones DL, Sönksen PH (2003).
Psychological effects of withdrawal of growth hormone therapy from adults with
growth hormone deficiency. Clin Endocrinol (Oxf). 59:467-475.
Mintzer MZ, Stitzer ML (2002). Cognitive impairment in methadone maintenance patients.
Drug Alcohol Depend. 67:41-51.
Muriach M, López-Pedrajas R, Barcia JM, Sanchez-Villarejo MV, Almansa I, Romero FJ
(2010). Cocaine causes memory and learning impairments in rats: involvement of
nuclear factor kappa B and oxidative stress, and prevention by topiramate. J
Neurochem. 114:675-684.
Moghaddam B (2004). Targeting metabotropic glutamate receptors for treatment of the
cognitive symptoms of schizophrenia. Psychopharmacology (Berl). 174:39-44.
Nash RJ, Heimburg-Molinaro J, Nash RJ (2009). Heparin binding epidermal growth factor-
like growth factor reduces ethanol-induced apoptosis and differentiation in human
embryonic stem cells. Growth Factors. 27:362-369.
Nestor LJ, Ghahremani DG, Monterosso J, London ED (2011). Prefrontal hypoactivation
during cognitive control in early abstinent methamphetamine-dependent subjects.
Psychiatry Res. 194(:287-295
Nixon K, Crews FT (2002). Binge ethanol exposure decreases neurogenesis in adult rat
hippocampus. J Neurochem. 83:1087-1093.
Nixon K, McClain JA (2010). Adolescence as a critical window for developing an alcohol use
disorder: current findings in neuroscience. Curr Opin Psychiatry. 23:227-232.
Nulsen CE, Fox AM, Hammond GR (2010). Differential effects of ecstasy on short-term and
working memory: a meta-analysis. Neuropsychol Rev. 20:21-32.
Nyberg F (2000). Growth hormone in the brain: characteristics of specific brain targets for
the hormone and their functional significance. Front Neuroendocrinol. 21:330-348.
Nyberg F (2007). Growth hormone and brain function. In Ranke MB, Price DA, Reiter EO
(eds.) Growth Hormone Therapy in Pediatrics. 20 years of KIGS. Karger, Basel, pp
Nyberg F (2009). The role of the somatotrophic axis in neuroprotection and
neuroregeneration of the addictive brain. Int Rev Neurobiol. 88:399-427.
O'Kusky JR, Ye P, D'Ercole AJ (2000). Insulin-like growth factor-I promotes neurogenesis
and synaptogenesis in the hippocampal dentate gyrus during postnatal
development. J Neurosci. 20:8435-8442.
Olive MF (2009). Metabotropic glutamate receptor ligands as potential therapeutics for
addiction. Curr Drug Abuse Rev. 2:83-98.
Olive MF (2010). Cognitive effects of Group I metabotropic glutamate receptor ligands in the
context of drug addiction. Eur J Pharmacol. 639:47-58.
Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW
(2000). Profiles of cognitive dysfunction in chronic amphetamine and heroin
abusers. Neuropsychopharmacology. 23:113-126
Parrott AC, Lasky J (1998). Ecstasy (MDMA) effects upon mood and cognition: before,
during and after a Saturday night dance. Psychopharmacology (Berl). 139:261-268.
Brain Damage – Bridging Between Basic Research and Clinics
Reichel CM, Ramsey LA, Schwendt M, McGinty JF, See RE (2011). Methamphetamine-
induced changes in the object recognition memory circuit. Neuropharmacology.
2011 Nov 18. [Epub ahead of print].
Reske M, Eidt CA, Delis DC, Paulus MP (2010). Nondependent stimulant users of cocaine
and prescription amphetamines show verbal learning and memory deficits. Biol
Psychiatry. 68:762-769.
Ridderinkhof KR, van den Wildenberg WP, Segalowitz SJ, Carter CS (2004). Neurocognitive
mechanisms of cognitive control: the role of prefrontal cortex in action selection,
response inhibition, performance monitoring, and reward-based learning. Brain
Cogn. 56:129-140.
Rogers G, Elston J, Garside R, et al. (2009) The harmful health effects of recreational ecstasy:
A systematic review of observational evidence. Health Technol Assess 13: 1–315.
Samuelson KW (2011). Post-traumatic stress disorder and declarative memory functioning: a
review. Dialogues Clin Neurosci. 13:346-351.
Santini E, Muller RU, Quirk GJ (2001). Consolidation of extinction learning involves transfer
from NMDA-independent to NMDA-dependent memory. J Neurosci. 21:9009-9017.
Seiler AE, Ross BN, Green JS, Rubin R (2000). Differential effects of ethanol on insulin- like
growth factor-I receptor signaling. Alcohol Clin Exp Res. 24:140-148.
Silva AP, Martins T, Baptista S, Gonçalves J, Agasse F, Malva JO (2010). Brain injury
associated with widely abused amphetamines: neuroinflammation, neurogenesis
and blood-brain barrier. Curr Drug Abuse Rev. 3:239-254
Simonyi A, Schachtman TR, Christoffersen GR (2005).The role of metabotropic glutamate
receptor 5 in learning and memory processes. Drug News Perspect. 18:353-361.
Soyka M, Limmer C, Lehnert R, Koller G, Martin G, Küfner H, Kagerer S, Haberthür A
(2011). A comparison of cognitive function in patients under maintenance
treatment with heroin, methadone, or buprenorphine and healthy controls: an open
pilot study. Am J Drug Alcohol Abuse. 37:497-508.
Spain JW, Newsom GC (1991). Chronic opioids impair acquisition of both radial maze and
Y-maze choice escape. Psychopharmacology (Berl). 105:101-106
Stramiello M, Wagner JJ (2010). Cocaine enhancement of long-term potentiation in the CA1
region of rat hippocampus: lamina-specific mechanisms of action. Synapse. 64:644-
Sudai E, Croitoru O, Shaldubina A, Abraham L, Gispan I, Flaumenhaft Y, Roth-Deri I, Kinor
N, Aharoni S, Ben-Tzion M, Yadid G (2011). High cocaine dosage decreases
neurogenesis in the hippocampus and impairs working memory. Addict Biol.
Sullivan EV, Pfefferbaum A (2005). Neurocircuitry in alcoholism: a substrate of disruption
and repair. Psychopharmacology (Berl). 180:583-594.
Sun LY, Al-Regaiey K, Masternak MM, Wang J, Bartke A (2005). Local expression of GH and
IGF-1 in the hippocampus of GH-deficient long-lived mice. Neurobiol Aging.
Svensson AL, Bucht N, Hallberg M, Nyberg F (2008). Reversal of opiate-induced apoptosis
by human recombinant growth hormone in murine foetus primary hippocampal
neuronal cell cultures. Proc Natl Acad Sci U S A. 105:7304-7308.
Cognitive Impairments in Drug Addicts 243
Taffe MA, Kotzebue RW, Crean RD, Crawford EF, Edwards S, Mandyam CD (2010). Long-
lasting reduction in hippocampal neurogenesis by alcohol consumption in
adolescent nonhuman primates. Proc Natl Acad Sci U S A.107:11104-11109.
Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ (1999).
Genetic enhancement of learning and memory in mice. Nature. 401:63-69.
Taqi MM, Bazov I, Watanabe H, Sheedy D, Harper C, Alkass K, Druid H, Wentzel P, Nyberg
F, Yakovleva T, Bakalkin G (2011). Prodynorphin CpG-SNPs associated with
alcohol dependence: elevated methylation in the brain of human alcoholics. Addict
Biol. 16:499-509.
Tateno M, Ukai W, Ozawa H, Yamamoto M, Toki S, Ikeda H, Saito T (2004). Ethanol
inhibition of neural stem cell differentiation is reduced by neurotrophic factors.
Alcohol Clin Exp Res. 2004 Aug;28(8 Suppl Proceedings):134S-138S.
Tedstone D, Coyle K (2004). Cognitive impairments in sober alcoholics: performance on
selective and divided attention tasks. Drug Alcohol Depend. 75:277-286.
Thompson AM, Swant J, Wagner JJ (2005). Cocaine-induced modulation of long-term
potentiation in the CA1 region of rat hippocampus. Neuropharmacology. 49:185–
Thornwall-Le Greves M, Zhou Q, Lagerholm S, Huang W, Le Greves P, Nyberg F (2001).
Morphine decreases the levels of the gene transcripts of growth hormone receptor
and growth hormone binding protein in the male rat hippocampus and spinal cord.
Neurosci Lett. 304:69-72
Tramullas M, Martínez-Cué C, Hurlé MA (2007). Chronic methadone treatment and
repeated withdrawal impair cognition and increase the expression of apoptosis-
related proteins in mouse brain. Psychopharmacology (Berl). 193:107-120.
Tzschentke TM, Schmidt WJ (2003). Glutamatergic mechanisms in addiction. Mol
Psychiatry. 8:373-382.
van Dam PS, Aleman A, de Vries WR, Deijen JB, van der Veen EA, de Haan EH,
Koppeschaar HP (2000). Growth hormone, insulin-like growth factor I and
cognitive function in adults. Growth Horm IGF Res. 10 Suppl B:S69-73.
Vardakou I, Pistos C, Spiliopoulou Ch (2011). Drugs for youth via Internet and the example
of mephedrone. Toxicol Lett. 201:191-195.
Venkatesan A, Uzasci L, Chen Z, Rajbhandari L, Anderson C, Lee MH, Bianchet MA, Cotter
R, Song H, Nath A (2011). Impairment of adult hippocampal neural progenitor
proliferation by methamphetamine: role for nitrotyrosination. Mol Brain. 2011 Jun
Weiss C, Disterhoft JF (2011). Exploring prefrontal cortical memory mechanisms with
eyeblink conditioning. Behav Neurosci. 125:318-326.
Wolf ME (1998). The role of excitatory amino acids in behavioral sensitization to
psychomotor stimulants. Prog Neurobiol. 54:679-720. Review
Xu TX, Ma Q, Spealman RD, Yao WD (2010). Amphetamine modulation of long-term
potentiation in the prefrontal cortex: dose dependency, monoaminergic
contributions, and paradoxical rescue in hyperdopaminergic mutant. J Neurochem.
Brain Damage – Bridging Between Basic Research and Clinics
Yang Z, Xie J, Shao YC, Xie CM, Fu LP, Li DJ, Fan M, Ma L, Li SJ (2009). Dynamic neural
responses to cue-reactivity paradigms in heroin-dependent users: an fMRI study.
Hum Brain Mapp. 30:766-775.
Zhai QZ, Lai Z, Yukhananov R, Roos P, Nyberg F (1995). Decreased binding of growth
hormone in the rat hypothalamus and choroid plexus following morphine
treatment. Neurosci Lett. 23;184:82-85
Zhao MG, Toyoda H, Lee YS, Wu LJ, Ko SW, Zhang XH, Jia Y, Shum F, Xu H, Li BM, Kaang
BK, Zhuo M. Roles of NMDA NR2B subtype receptor in prefrontal long- term
potentiation and contextual fear memory. Neuron. 2005; 47:859-872.
... Chronic use: impaired prose recall and cognitive function (Colzato et al., 2012;Freeman et al., 2012) Short term: increased cognitive function similar to other stimulants (Nyberg, 2012) Similar effects to other stimulants, specifically ecstasy (Freeman et al., 2012;Nyberg, 2012) Decreases working memory and longterm memory (den Hollander et al., 2012;Motbey et al., 2012) Similar to other stimulants (Motbey et al., 2012;North et al., 2013) ...
... Chronic use: impaired prose recall and cognitive function (Colzato et al., 2012;Freeman et al., 2012) Short term: increased cognitive function similar to other stimulants (Nyberg, 2012) Similar effects to other stimulants, specifically ecstasy (Freeman et al., 2012;Nyberg, 2012) Decreases working memory and longterm memory (den Hollander et al., 2012;Motbey et al., 2012) Similar to other stimulants (Motbey et al., 2012;North et al., 2013) ...
... Over the past decades, the impact of drug abuse on cognitive abilities in addicts has been surveyed by many different clinical laboratories and basic sciences. Although it has long been known that alcoholism is associated with memory and learning deficits and appears to accelerate aging processes, the negative effects of chronic drug use on cognitive function in recent years have become evident during (14,15). ...
... Patients with mental illness are at high risk for substance abuse, and the adverse impact on cognition may be particularly deleterious in combination with cognitive problems related to their mental disorders." Effects of drug abuse on cognitive impairment are further reviewed by Nyberg [137]. Several preclinical paradigms have been used to measure potential effects on drug abuse. ...
5-hydroxytryptamine6 receptor (5-HT6R) antagonists have shown efficacy in animal models for cognitive impairment in multiple cognitive domains relevant for schizophrenia. Improvements were found with 5-HT6R antagonists in preclinical tests for episodic memory, social cognition, executive function, working memory and several other tests for both learning and memory. In contrast, there is little evidence for efficacy on attention. It will be interesting to further investigate 5-HT6R antagonists in neurodevelopmental animal models which are based on prenatal exposure to specific environmental insults, and are characterized by a high level of face, construct and predictive validity for cognitive impairments associated with schizophrenia. It is also important to do more add-on preclinical studies of 5-HT6 antagonists with antipsychotics. Possible mechanisms of action to improve cognition have been described. 5-HT6R antagonists decrease GABA release and GABAergic interneuron excitability, which subsequently disinhibits glutamate and/or acetylcholine release and results in enhancement of synaptic plasticity. Furthermore, cognition could be improved by 5-HT6R antagonists, because these compounds increase the number of NCAM PSA-immunoreactive neurons in the dendate gyrus, inhibit mTOR and Fyn-tyrosine kinase and interact with DARPP-32. Interestingly, there is increasing preclinical evidence that could support additional benefits of 5-HT6R ligandson comorbid conditions in schizophrenia such as drug abuse, depression, anxiety, obesity andantipsychotic-induced EPS. Finally, we briefly give an overview of the 5-HT6R compounds that are currently in clinical development for the treatment of cognitive impairment in both schizophrenia and Alzheimer's disease.
... Recent research also indicates that chronic or subchronic administration of mephedrone causes a reduction in memory function in rats [7,38,41]. However, other data indicate that mephedrone increases cognitive function after an acute administration similarly to other stimulants [42]. Also, series of study show that a post-training injection of d-amphetamine improves memory storage processes in the consolidation phase [43]. ...
Full-text available
The purpose of our experiment was to examine the influence of co-administration of nicotine and mephedrone on anxiety-like behaviors, cognitive processes and the nicotine-induced behavioral sensitization as well as processes connected with induction of oxidative stress in the brain of male Swiss mice. The results revealed that co-administration of subthreshold doses of mephedrone and nicotine (0.05 mg/kg each) exerted marked anxiogenic profile in the elevated plus maze and displayed pro-cognitive action in the passive avoidance paradigm (nicotine 0.05 mg/kg and mephedrone 2.5 mg/kg). Furthermore, one of the main findings of the present study was that mephedrone, administered alone at the dose not affecting locomotor activity of mice (1 mg/kg), enhanced the expression of nicotine-induced locomotor sensitization. Moreover, mephedrone administered with nicotine decreased general antioxidant status and catalase activity as well as antioxidant enzymes activity in the hippocampus and prefrontal cortex and increased concentration of malondialdehyde, an indicator of lipid peroxidation processes. Considering the likelihood that mephedrone is taken as a part of polydrug combination with nicotine, the effects of this combination on mammalian organisms have been confirmed in our study. Understanding the consequences of co-administration of psychoactive substances on the central nervous system and oxidative processes in the brain provide the important toxicological significance, and may be useful in polydrug intoxication treatment. Electronic supplementary material The online version of this article (doi:10.1007/s11064-015-1566-5) contains supplementary material, which is available to authorized users.
Full-text available
Objective: The present study aimed at comparing the learning and memory ability between methamphetamine- ant opiate-dependent patients and healthy people. Method: A causal-comparative research method was employed in this study. The statistical population of the study included the men with methamphetamine and opioid dependence and healthy men in Tehran. The sample consisted of 20 men with methamphetamine, 17 opioid dependent men, and 20 healthy men who were selected via convenience sampling method: In this research, Rey Auditory Verbal Learning Test and Depression Anxiety Stress Scales (DASS) were used for data collection. Results: The results of this study showed that drug dependent persons had lower scores in learning ability and memory than the healthy group. The opioid group was weaker in the recall ability and recognition of information. The methamphetamine group showed more repetition in the recall and interference in the recognition of the words. Conclusion: The drug-dependent group undergone a higher degree of harm to learning and memory ability. Further study of the vulnerability of these groups provides constructive tips for the arrangement of appropriate interventions in the realm of rehabilitation.
Over the past years it has become evident that repeated exposure to a variety of psychoactive stimulants, like amphetamine, cocaine, MDMA (3,4-methylenedioxy-N-methylamphetamine), methylphenidate and nicotine may produce profound behavioral changes as well as structural and neurochemical alterations in the brain that may persist long after drug administration has ceased. These stimulants have been shown to produce long-lasting enhanced embranchments of dendrites and increasing spine density in brain regions linked to behavioral sensitization and compulsive patterns characteristic of drug seeking and drug addiction. In this regard, addiction to stimulant drugs represents a compulsory behavior that includes drug seeking, drug use and drug craving, but is also characterized as a cognitive disorder. In this article, recent findings regarding the impact of central stimulants on plasticity in brain regions of relevance for addictive behavior will be highlighted. A particular focus will be given to changes in neuroplasticity that occur in areas related to memory and cognition. Possible routes for the reversal of altered brain plasticity will also be discussed.
Full-text available
Recent studies have demonstrated that growth hormone (GH) may exert profound effects on the central nervous system (CNS). A special interest has been directed to the ability of GH to enhance cognitive capability in individuals with deficiency of the hormone. In the present study we have studied the effect of recombinant human GH (rhGH) on learning and memory in hypophys-ectomized male rats using an elevated eight-arm radial maze. We observed that rats receiving rhGH exhibited a dose-dependent improvement in their ability to respond in the task. This was indicated by a shorter latency to first correct response, an increased number of correct responses and fewer errors in animals receiving the hormone. It was concluded that impaired cognitive ability induced by removal of the GH-producing pituitary gland could be counteracted by hormone replacement therapy.
Full-text available
Hebb's rule (1949) states that learning and memory are based on modifications of synaptic strength among neurons that are simultaneously active. This implies that enhanced synaptic coincidence detection would lead to better learning and memory. If the NMDA (N-methyl-D-aspartate) receptor, a synaptic coincidence detector, acts as a graded switch for memory formation, enhanced signal detection by NMDA receptors should enhance learning and memory. Here we show that overexpression of NMDA receptor 2B (NR2B) in the forebrains of transgenic mice leads to enhanced activation of NMDA receptors, facilitating synaptic potentiation in response to stimulation at 10-100 Hz. These mice exhibit superior ability in learning and memory in various behavioural tasks, showing that NR2B is critical in gating the age-dependent threshold for plasticity and memory formation. NMDA-receptor-dependent modifications of synaptic efficacy, therefore, represent a unifying mechanism for associative learning and memory. Our results suggest that genetic enhancement of mental and cognitive attributes such as intelligence and memory in mammals is feasible.
Alcohol affects approximately 1% (40,000) of new born infants each year and is the main preventable cause of mental retardation in the US. Ethanol alters cell signaling and promotes apoptosis and differentiation. Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF family of growth factors, has been reported to prevent apoptosis and differentiation. We treated human embryonic stem cells (hESCs) with ethanol (20 mM) to reflect casual drinking, with and without HB-EGF to measure its ability to prevent ethanol-induced apoptosis and differentiation. Apoptosis was measured by DNA fragmentation (terminal dUTP nick-end labeling assays) and activated caspase-3, while differentiation was accessed by SSEA-1 and OCT-3/4; western blotting assessed MAPK signaling. HB-EGF reduced SSEA-1 and elevated OCT-3/4, while reducing the amount of activated caspase-3 and DNA fragmentation. Western blot analysis showed HB-EGF prevents ethanol from altering MAPK phosphorylation. This data suggests that ethanol-induced apoptosis was reduced by HB-EGF, while hESC pluripotency was maintained.
Activation of the insulin-like growth factor I receptor (IGF-IR) by its ligands IGF-I and IGF-II induces cell proliferation and protects against apoptosis. Ethanol inhibits IGF-IR tyrosine autophosphorylation, which subsequently interferes with the activation of key downstream signaling mediators including insulin-receptor substrate-1, phosphatidylinositol 3-kinase, and mitogen-activated protein (MAP) kinase. The ethanol-induced inhibition of IGF-IR signaling reduces mitogenesis and enhances apoptosis. In the current study, we demonstrate that the antiproliferative action of ethanol can be modulated by differential sensitivity of the autophosphorylation of the IGF-IR to ethanol. A series of subclones was generated from 3T3 cells that express the human IGF-IR. There was considerable variability in the ability of ethanol to inhibit IGF-I-dependent IGF-IR tyrosine autophosphorylation and MAP kinase activation, despite equivalent IGF-IR expression. The IGF-IR was completely resistant to a high concentration of ethanol (150 mM) in several subclones. The sensitivity of IGF-IR autophosphorylation to ethanol correlated directly with the inhibition of IGF-I-mediated MAP kinase activation and cell proliferation. Resistant subclones exhibited features of the transformed phenotype including high MAP kinase activity, partial loss of contact inhibition, and the development of foci at confluency. The IGF-IR isolated from ethanol-resistant cells was similarly resistant to ethanol in autophosphorylation reactions in vitro, whereas ethanol inhibited the autophosphorylation of IGF-IR obtained from sensitive cells. Our findings are the first to demonstrate the modulation of ethanol sensitivity of a tyrosine kinase receptor, and they provide a molecular basis for differential effects of ethanol on cell proliferation.
Objective: Cocaine dependence is characterized by stress system dysregulation, including elevated cortisol activity, emotional negativity, and behavioral disinhibition. High levels of stress and glucocorticoids are also known to affect learning, memory and executive function. Therefore, we examined the relationships between chronic cocaine use, elevated distress and learning and memory dysfunction in abstinent cocaine dependent (CD) individuals, and whether these measures were associated with cocaine relapse outcomes. Method: Stress was assessed in 36 inpatient treatment engaged CD individuals and 36 demographically matched healthy control (HC) participants using the Perceived Stress Scale (PSS) and repeated morning salivary cortisol levels over three consecutive days. The Rey Auditory Verbal Learning Test (RAVLT) was conducted to measure verbal learning, memory, and executive function. Prospective assessment of cocaine use outcomes during 90 days following discharge from inpatient treatment was also conducted. Results: CD patients showed higher levels of distress compared to controls in PSS scores and cortisol levels. They also demonstrated a significantly reduced learning curve, and fewer correct responses and more errors on recognition. Elevated cortisol was significantly associated with worse RAVLT performance in CD patients. Poor memory scores, but not distress measures, were significantly associated with greater cocaine use after inpatient treatment. Conclusions: These findings are the first to demonstrate that learning and memory deficits in CD individuals are associated with enhanced cortisol and with cocaine use outcomes after inpatient treatment. The findings are consistent with recent addiction models suggesting that chronic cocaine-related neuroadaptations affects learning and memory function, which in turn, influences drug use outcomes.